Brinzolamide/latanoprost

Drug Profile

Brinzolamide/latanoprost

Alternative Names: Latanoprost/brinzolamide

Latest Information Update: 08 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adapt Produtos Oftalmologicos
  • Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules; Sulfonamides; Thiazines
  • Mechanism of Action Carbonic anhydrase inhibitors; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Dec 2014 Adapt Produtos Oftalmologicos terminates phase III trial in Ocular hypertension and Glaucoma in Brazil (NCT01721707) prior to initiation
  • 05 Nov 2012 Clinical trials in Glaucoma in Brazil (Ophthalmic)
  • 05 Nov 2012 Clinical trials in Ocular hypertension in Brazil (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top